Bevacizumab combined with re-irradiation in recurrent glioblastoma
BackgroundGlioblastoma is characterized by rich vasculature and abnormal vascular structure and function. Currently, there is no standard treatment for recurrent glioblastoma (rGBM). Bevacizumab (BEV) has established role of inhibiting neovascularization, alleviating hypoxia in the tumor area and ac...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2022-08-01
|
| Schriftenreihe: | Frontiers in Oncology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fonc.2022.961014/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|